David Evans

Dr. David Evans


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JMJoel Morris
Joel Morris
MKMark W. Kunkel
Mark W. Kunkel
SWStephen L. White
Stephen L. White
DWDonn G. Wishka
Donn G. Wishka
OLOmar D. Lopez
Omar D. Lopez
BTBeverly A. Teicher
Beverly A. Teicher
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.

9 January 2024 in NAR Cancer
Verified
Journal Article
Open access
PDF file
WKWookhyun Kim
Wookhyun Kim
ZYZhou Ye
Zhou Ye
VSVera Simonenko
Vera Simonenko
ASAashirwad Shahi
Aashirwad Shahi
AMAsra Malikzay
Asra Malikzay
DEDavid Evans
David Evans
Upregulation of TGFβ and Cox2 in the tumor microenvironment results in blockade of T-cell penetration into the tumor. Without access to tumor antigens, the T-cell response will not benefit from administration of the immune checkpoint antibodies. We created an intravenous polypeptide nanoparticle that can deliver two siRNAs (silencing TGFβ and Cox2). Systemic administration in mice, bearing a syngeneic orthotopic hepatocellular carcinoma (HCC), delivers the siRNAs to various cells in the liver, and significantly reduces the tumor. At 2 mg/kg (BIW) the nanoparticle demonstrated a single agent action and induced tumor growth inhibition to undetectable levels after five doses. Reducing the siRNAs to 1mg/kg BIW demonstrated greater inhibition in the presence of PD-L1 mAbs. After only three doses BIW, we could still recover a smaller tumor and, in tumor sections, showed an increase in penetration of CD4+ and CD8+ T-cells deeper into the remaining tumor that was not evident in animals treated with non-silencing siRNA. The combination of TGFβ and Cox2 siRNA co-administered in a polypeptide nanoparticle can act as a novel therapeutic alone against HCC and may augment the activity of the immune checkpoint antibodies. Silencing TGFβ and Cox2 converts an immune excluded (cold) tumor into a T-cell inflamed (hot) tumor.

11 August 2020 in NAR Cancer
Verified
Journal Article
Open access
PDF file
VSVera Simonenko
Vera Simonenko
XLXiaoyong Lu
Xiaoyong Lu
EREric Roesch
Eric Roesch
DMDaniel Mutisya
Daniel Mutisya
CSChunbo Shao
Chunbo Shao
DEDavid Evans
David Evans
The non-nucleoside analog gemcitabine has been the standard of care for treating pancreatic cancer. The drug shows good potency in pancreatic cancer cells in vitro but, due to poor bioavailability, requires administration in large doses by infusion and this systemic exposure results in significant toxicity for the patient. Genes have been identified that, when silenced by siRNA, synergize with gemcitabine treatment and offer a means of reducing the gemcitabine dosage required for efficacy. However, benefiting from the synergism between the two agents requires that the gemcitabine and siRNA penetrate the same cells. To ensure co-delivery, we incorporated gemcitabine covalently within siRNAs against targets synergistic with gemcitabine (CHK1 or RAD17). We demonstrated that specific bases within an siRNA can be replaced with gemcitabine to increase efficacy. The result is a single drug molecule that simultaneously co-delivers gemcitabine and a synergistic siRNA. The siRNA–gemcitabine constructs demonstrate a 5–30-fold improvement in potency compared with gemcitabine alone. Co-delivering a CHK1 siRNA–gemcitabine construct together with a WEE1 siRNA resulted in a 10-fold improvement in IC50 compared with gemcitabine alone. These constructs demonstrate efficacy across a wide array of pancreatic tumor cells and may represent a novel therapeutic approach for treating pancreatic cancer.

9 January 2026 in NAR Cancer
Verified
Journal Article
Open access
DWDeling Wang
Deling Wang
WJWanying Jia
Wanying Jia
JLJinping Lian
Jinping Lian
JZJin Zhang
Jin Zhang
XRXiangyu Ren
Xiangyu Ren
DEDavid Evans
David Evans
Late-stage melanoma can metastasize to organs beyond the skin, such as lungs, liver, brain, and bone, resulting in reduced patient survival time. The incidence of melanoma is currently growing worldwide, and novel therapeutic options are needed to prevent its dissemination and to improve therapeutic results. This paper describes the use of small interfering RNA (siRNA) to silence expression of TGFβ1 and VEGFR2 as an alternative approach for melanoma treatment. These two therapeutic targets have been well-documented in tumor immune modulation and tumor angiogenesis within the tumor microenvironment (TME). Two potent siRNA candidates targeting TGFβ1 or VEGFR2 were identified with 100% identity to sequences of mouse, non-human primate (NHP), and humans. The combination of the two siRNAs was formulated with a clinically validated polypeptide nanoparticle (PNP) carrier. This PNP-packaged siRNA formulation, STP355, administered intravenously in mice bearing syngeneic melanoma tumors, demonstrated silencing of both targets and a reduction in tumor growth. STP355 also reduced tumor weight significantly, without the toxicity observed with cisplatin, resulting in prolonged survival of mice compared with this small molecule. It increased immune cell penetration into TME and reduced metastases to the lung. STP355 was more efficacious than, and somewhat additive with, immune checkpoint inhibitory monoclonal antibodies.

16 September 2024
Verified
Other
Open access
JMJoel Morris
Joel Morris
MKMark W. Kunkel
Mark W. Kunkel
SWStephen L. White
Stephen L. White
DWDonn G. Wishka
Donn G. Wishka
OLOmar D. Lopez
Omar D. Lopez
BTBeverly A. Teicher
Beverly A. Teicher
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource